Catalog No.: PC-38676Not For Human Use, Lab Use Only.
Libvatrep (SAF312) is a potent, selective non-competitive inhibitor/antagonist of the transient receptor potential cation channel subfamily V member 1 (TRPV1), shows potential for treatment of ocular surface pain.
Libvatrep (SAF312) is a potent, selective non-competitive inhibitor/antagonist of the transient receptor potential cation channel subfamily V member 1 (TRPV1), shows potential for treatment of ocular surface pain.
SAF312 is >150-fold selective for TRPV1 when tested against a panel of 18 TRP channels.
SAF312 inhibited capsaicin, low pH 2-(n-morpholino)ethanesulfonic acid (MES, pH 5.5), anandamide (AEA), and N-arachidonoyl dopamine (NADA) stimulated human TRPV1 with IC50 values of 12, 16, 7.3 and 36 nM, respectively in a selective, non-competitive, and reversible manner.
1. Quint Medley, et al. ARVO Annual Meeting Abstract, June 2021. In-vitro and In-vivo pharmacology of SAF312 as a TRPV1 inhibitor for ocular surface pain.
